macupatide (GIPR Agonist LA II) / Eli Lilly - LARVOL DELTA

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=105 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A long-acting glucose dependent insulinotropic polypeptide receptor agonist improves insulin sensitivity and beta cell function in subjects with type 2 diabetes (EASD 2024) - P1 | "Materials and In a 12-week randomized controlled trial, subjects with T2D were enrolled to evaluate the effect of 20 mg LY3532226 weekly (LAGIPRA), 1.5 mg dulaglutide weekly, or LAGIPRA plus dulaglutide weekly on insulin sensitivity and beta-cell function. In patients with T2D, both LAGIPRA and dulaglutide improved body weight and HbA1c, but their effects on insulin sensitivity and beta-cell function differed. LAGIPRA primarily improved insulin sensitivity, whereas dulaglutide had a greater effect on insulin secretion. These effects on insulin sensitivity and secretion were additive when dulaglutide and LAGIPRA were combined."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=105 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=92 | Active, not recruiting | Sponsor: Eli Lilly and Company | Phase classification: P1b ➔ P1

Phase classification • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1b | N=92 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1b | N=92 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1b | N=92 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Healthy Participants (clinicaltrials.gov) - P1; N=41; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion